Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Equity Ratio (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Equity Ratio data on record, last reported at 0.61 in Q4 2025.

  • For Q4 2025, Equity Ratio rose 2.57% year-over-year to 0.61; the TTM value through Dec 2025 reached 0.61, up 2.57%, while the annual FY2025 figure was 0.61, 2.57% up from the prior year.
  • Equity Ratio reached 0.61 in Q4 2025 per TARS's latest filing, down from 0.63 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.95 in Q2 2021 and bottomed at 0.6 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.77, with a median of 0.78 recorded in 2023.
  • Peak YoY movement for Equity Ratio: soared 586.45% in 2021, then fell 20.74% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.93 in 2021, then decreased by 9.16% to 0.85 in 2022, then dropped by 12.35% to 0.74 in 2023, then dropped by 19.73% to 0.6 in 2024, then grew by 2.57% to 0.61 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.61 in Q4 2025, 0.63 in Q3 2025, and 0.67 in Q2 2025.